# Regeneron (REGN) — Analyst Forecast

REGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/regn/forecast

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | UBS | Upgraded | Neutral → Buy | $978.00 |
| Oct 8, 2026 | RBC Capital | Maintained | Sector Perform | $810.00 |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | $780.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | $779.00 |
| Oct 6, 2026 | JP Morgan | Maintained | Overweight | $950.00 |
| Oct 1, 2026 | Argus Research | Upgraded | Hold → Buy | $850.00 |
| Oct 1, 2026 | Jefferies | Maintained | Buy | $930.00 |
| Sep 29, 2026 | RBC Capital | Maintained | Sector Perform | $737.00 |
| Sep 10, 2026 | HSBC | Maintained | Buy | $920.00 |
| Aug 17, 2026 | Leerink Partners | Maintained | Market Perform | $824.00 |
| Aug 3, 2026 | Guggenheim | Maintained | Buy | $1,030.00 |
| Aug 3, 2026 | Citigroup | Maintained | Neutral | $740.00 |
| Jul 31, 2026 | Truist Securities | Maintained | Buy | $772.00 |
| Jul 31, 2026 | Wells Fargo | Maintained | Equal-Weight | $750.00 |
| Jul 31, 2026 | Cantor Fitzgerald | Maintained | Overweight | $795.00 |
| Jul 31, 2026 | Morgan Stanley | Maintained | Equal-Weight | $758.00 |
| Jul 31, 2026 | RBC Capital | Maintained | Sector Perform | $737.00 |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | $1,000.00 |
| Jul 9, 2026 | Piper Sandler | Maintained | Overweight | $854.00 |
| Jul 8, 2026 | Morgan Stanley | Maintained | Equal-Weight | $730.00 |

## Frequently Asked Questions

### What is the latest analyst rating on REGN?

On Oct 15, 2026, UBS upgraded Regeneron to Buy with a price target of $978.00.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).